Alere receives consents under three note series to allow unit's IPO

By Tali Rackner

Norfolk, Va., June 5 – Alere Inc. received sufficient consents for its 7¼% senior notes due 2018, its 8 5/8% senior subordinated notes due 2018 and its 6½% senior subordinated notes due 2020, according to an 8-K filing with the Securities and Exchange Commission.

As previously reported, the company solicited consents for waivers and amendments to the note indentures to allow the proposed initial public offering of subsidiary BBI Diagnostics Group plc.

Alere is not required to make the modifications operative by paying the consent fees or to consummate the BBI transaction. If the company were to cause the modifications to become operative, it would pay about $9.45 million of fees in connection with the amendments.

The solicitation ended at 5 p.m. ET on June 4.

Jefferies LLC was the solicitation agent. Ipreo LLC (888 593-9546 or 212 849-3880) was the information and tabulation agent.

Alere is a Waltham, Mass.-based provider of near-patient diagnosis, monitoring and health management.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.